Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 136 (5), 1601-1608
- https://doi.org/10.1053/j.gastro.2009.01.053
Abstract
No abstract availableFunding Information
- American College of Gastroenterology
- National Institutes of Health (K24DK078154-03)
- U.S. Department of Veterans Affairs
- Health Services Research and Development (IIR 02-081)
This publication has 30 references indexed in Scilit:
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptorJournal of Hepatology, 2005
- Methods to assess intended effects of drug treatment in observational studies are reviewedJournal of Clinical Epidemiology, 2004
- Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse modelsCarcinogenesis: Integrative Cancer Research, 2003
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Effect of HMG-COA reductase inhibitors on proliferation and ECM protein synthesis by rat hepatic stellate cellsJournal of Hepatology, 2001
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme a reductase, on the growth of human ito cellsJournal of Hepatology, 1994
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988